hrp0098p1-166 | Growth and Syndromes 2 | ESPE2024

Growth hormone therapy in patient with overlap syndrome: growth outcome after one year of treatment.

Luppino Giovanni , Franchina Francesca , Lugarà Cecilia , Pepe Giorgia , Anna Morabito Letteria , Aversa Tommaso , Wasniewska Malgorzata , Corica Domenico

Background: SET domain-containing 5 (SETD5) is a member of the protein lysine-methyltransferase family that regulates gene expression. SETD5 gene mutations cause disorders of the epigenetic machinery which determinate phenotypic overlap characterized by several abnormalities. Recently, SEDT5 gene variants have been described in patients with KBG and Cornelia de Lange syndromes. Pathogenic variants of SETD5 gene are primarily associated with intellectual delay ...

hrp0098p3-260 | Thyroid | ESPE2024

Evolution of subclinical hypothyroidism in infancy: a single-center longitudinal retrospective cohort study

Franchina Francesca , Lugarà Cecilia , Coco Roberto , Pepe Giorgia , Anna Morabito Letteria , Li Pomi Alessandra , Corica Domenico , Wasniewska Malgorzata , Aversa Tommaso

Background: Management of subclinical hypothyroidism (SH) in infancy is still controversial. According to the European Guidelines for Congenital Hypothyroidism (CH), in case of TSH levels between 6 and 20 µUI/ml, both levothyroxine (L-T4) therapy and a wait-and-see approach can be considered.Aim: to describe the evolution of SH diagnosed in newborns recalled by neonatal screening (TSH values ≥7µUI/ml)....